When the future of ADCs and bispecifics collide
Challenges and opportunities go hand in hand with early drug development
Which Thunderbirds are Go in this niche?!
The best marketing cannot solve a major product weakness in your compound
Red and green flags to watch out for in relapsed SCLC
On biomarkers, acquired resistance and immune escape, oh my!
Which combinations make rational sense and which might see action in the clinic?
Where is the ADC space heading and waht issues need to be addressed?
Early stage oncology new product development is a rather strange beast at times. On the one hand is the…
Where to pivot next? That's the question...
Can bicyclic toxin and radio conjuates do a better job than ADCs and RLTs?
Who's going to be roaring forward?
It's time to challenge our thinking on cytokines
Can a new generation of bispecifics change our mind about a particular target?
Switching focus in the critical KRAS pocket
Segueing between preclinical and clinical data
Next generation agents or a new drug class?
In beast mode – or not?
Where epigenetics and synthetic lethality converge
How protecting both the on and the blindside may delay resistance and improve outcomes
The AACR annual meeting is an opportunity to challenge established paradigms and scientific dogma. In…
How kicking things up a notch by thinking outside the box may pay dividends
Finding solutions for tough to drug targets
When the going gets tough, the tough get going...
An emerging research tool to watch out for in oncology new product development
A vertical and horizontal fishing expedition in new product development
Our 7th AACR Preview takes stock of an emerging class of anti-cancer agents
In 2011 we did an annual ASCO highlight video reel of what to watch out for. Three phase 1…
In our fifth preview from the AACR annual meeting being held in San Diego next month, we noticed some…
The good, the bad, and the ugly under belly of the next flurry of ADCs
W2W4 - what to watch for in an emerging oncology niche
Finding nuance and solutions amongst the clutter
What happens when multiple oncogenic pathways converge at the crossroads? An important aspect to watch out for heading into AACR24
